EL
ABBV icon

ERN LLC’s AbbVie ABBV Stock Holding History

ERN LLC’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$2.54M Buy
+16,581
New +$2.53M 2.84% 8

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ERN LLC's ABBV Position: Q2 2022 in Review

ERN LLC opened a new position in AbbVie (ABBV) in Q2 2022: 16,581 shares worth $2.54M. The stake represents 2.84% of the portfolio and ranks #8 among its holdings.

3,006 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

  • ERN LLC held 16,581 shares of AbbVie worth $2.54M as of Q2 2022.
  • AbbVie was a new ERN LLC position in Q2 2022.
  • AbbVie made up 2.84% of ERN LLC's portfolio in Q2 2022, its #8 holding.
  • 3,006 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on ERN LLC's 13F filing for Q2 2022, filed 13 Jul 2022.